The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival
Open accessAbstract
We have studied retrospectively 220 patients with cryptogenic fibrosing alveolitis (CFA) who were first seen between 1955-73 and had been followed up for at least four years until 1977. Seventy-seven patients had received no treatment and 143 had received corticosteroids. The only clinical difference between the groups was the age at presentation (untreated mean age 61 years±11 SD; treated mean age 56 years±11 SD p <0·001). The influence of corticosteroid treatment has been assessed both in terms of the clinical, radiographic, and physiological response after four to eight weeks and in terms of survival, using a log rank method of analysis. Of 143 treated cases 127 had detailed follow-up information. Seventy-two (57%) had substantial subjective improvement of breathlessness but only 22 (17%) of the total showed additional objective improvement. The only factors significantly distinguishing the 72 subjective responders from the 55 non-responders, and which therefore might be used as predictors of response, were a younger age at presentation (p <0·001) and less dyspnoea (p <0·02). Analysis of survival data demonstrated that treated patients who showed an early good response to steroids had a markedly better survival than non-responders (p <0·001). The survival curve for the untreated group lay between the two steroid groups. Analysis of the survival data suggests that steroid responsiveness relates particularly to a subgroup with an inherently better prognosis, which is characterised by a younger age and probably by a cellular histology not however necessarily typical of desquamative interstitial pneumonia. Nevertheless treatment appears to have an additional influence on survival especially in early disease, which is not observed in the untreated cases. A large number of factors are not related either to steroid responsiveness or to survival and these include the presence of associated “connective tissue” diseases, autoantibodies, and the duration of dyspnoea at presentation. It is concluded that biopsy information is valuable in assessment of potential to respond to steroids and that if steroid treatment is to be helpful it must be used at an early stage. The response is very variable and titration of the steroid dose against an individual patient9s response is likely to give better results than adherence to arbitrary dose schedules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Gross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Unilateral Lung Transplantation for Pulmonary Fibrosis
Toronto Lung Transplant Group* (1986) · New England Journal of Medicine · doi:10.1056/nejm198605013141802 · Cited by 655
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature
Nalysnyk, L., Cid-Ruzafa, J., Rotella, P., & Esser, D. (2012) · European Respiratory Review · doi:10.1183/09059180.00002512 · Cited by 552
International guidelines for the selection of lung transplant candidates
Maurer, J. R., Frost, A. E., Estenne, M., Higenbottam, T., & Glanville, A. R. (1998) · Transplantation · doi:10.1097/00007890-199810150-00033 · Cited by 562
Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia
Flaherty, K. R., Mumford, J. A., Murray, S., Kazerooni, E. A., Gross, B. H., Colby, T. V., Travis, W. D., Flint, A., Toews, G. B., Lynch, J. P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200209-1112oc · Cited by 513
Cryptogenic fibrosing alveolitis: clinical features and their influence on survival
Turner-Warwick, M., Burrows, B., & Johnson, A. (1980) · Thorax · doi:10.1136/thx.35.3.171 · Cited by 508
Self-citationNICHOLSON, A. G., COLBY, T. V., DUBOIS, R. M., HANSELL, D. M., & WELLS, A. U. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.6.2003049 · Cited by 489
New Serum Indicator of Interstitial Pneumonitis Activity
Nobuoki, K., Seishi, K., Yukikazu, A., Hirofumi, F., Michio, Y., & Mitoshi, A. (1989) · Chest · doi:10.1378/chest.96.1.68 · Cited by 486
Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis
Gibbons, M. A., MacKinnon, A. C., Ramachandran, P., Dhaliwal, K., Duffin, R., Phythian-Adams, A. T., van Rooijen, N., Haslett, C., Howie, S. E., Simpson, A. J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201010-1719oc · Cited by 466
Acute Exacerbation in Idiopathic Pulmonary Fibrosis
Kondoh, Y., Taniguchi, H., Kawabata, Y., Yokoi, T., Suzuki, K., & Takagi, K. (1993) · Chest · doi:10.1378/chest.103.6.1808 · Cited by 457
Anticoagulant Therapy for Idiopathic Pulmonary Fibrosis
Kubo, H., Nakayama, K., Yanai, M., Suzuki, T., Yamaya, M., Watanabe, M., & Sasaki, H. (2005) · Chest · doi:10.1378/chest.128.3.1475 · Cited by 440
Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., & Arimura, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.046 · Cited by 436
Raghu, G., Depaso, W. J., Cain, K., Hammar, S. P., Wetzel, C. E., Dreis, D. F., Hutchinson, J., Pardee, N. E., & Winterbauer, R. H. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.2.291 · Cited by 414
Meltzer, E. B., & Noble, P. W. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-8 · Cited by 407
Idiopathic Pulmonary Fibrosis: Predicting Response to Therapy and Survival
GAY, S. E., KAZEROONI, E. A., TOEWS, G. B., LYNCH, J. P., GROSS, B. H., CASCADE, P. N., SPIZARNY, D. L., FLINT, A., ANTHONY SCHORK, M., WHYTE, R. I., et al. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9703022 · Cited by 406
DANIIL, Z. D., GILCHRIST, F. C., NICHOLSON, A. G., HANSELL, D. M., HARRIS, J., COLBY, T. V., & du BOIS, R. M. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9903021 · Cited by 381
International Guidelines for the Selection of Lung Transplant Candidates
(1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.1.15812 · Cited by 365
Nicholson, A. G., Fulford, L. G., Colby, T. V., du Bois, R. M., Hansell, D. M., & Wells, A. U. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2109039 · Cited by 299
(1990) · European Respiratory Journal · doi:10.1183/09031936.93.03080937 · Cited by 290
Pulmonary fibrosis: cytokines in the balance
Coker, R., & Laurent, G. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.11061218 · Cited by 267
Corticosteroids for idiopathic pulmonary fibrosis
Richeldi, L., Davies, H. R. H. R., Spagnolo, P., & Luppi, F. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002880 · Cited by 219
DOUGLAS, W. W., RYU, J. H., SWENSEN, S. J., OFFORD, K. P., SCHROEDER, D. R., CARON, G. M., & DeREMEE, R. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.1.9709089 · Cited by 182
Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts
Mapel, D. W., Hunt, W. C., Utton, R., Baumgartner, K. B., Samet, J. M., & Coultas, D. B. (1998) · Thorax · doi:10.1136/thx.53.6.469 · Cited by 120
Rudd, R. M., Prescott, R. J., Chalmers, J. C., Johnston, I. D. A., & for the Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society (2007) · Thorax · doi:10.1136/thx.2005.045591 · Cited by 113
Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis
Wallace, W. A., Roberts, S. N., Caldwell, H., Thornton, E., Greening, A. P., Lamb, D., & Howie, S. E. (1994) · Thorax · doi:10.1136/thx.49.3.218 · Cited by 52
Metadata
- Authors
- Turner-Warwick, M., Burrows, B., & Johnson, A.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 1980-08-01
- Volume
- 35
- Issue
- 8
- Pages
- 593-599
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2023437751
- Cited by
- 244
- References
- 1
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.